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Background: We have investigated the ability of Mifepristone, an anti-progestin and anti-glucocorticoid drug, to
modulate the antitumor effect of current standard clinical treatment in glioblastoma xenografts.
Methods: The effect of radiation alone or combined with Mifepristone and Temozolamide was evaluated on tumor
growth in glioblastoma xenografts, both in terms of preferentially triggering tumor cell death and inhibiting
angiogenesis. Tumor size was measured once a week using a caliper and tumor metabolic-activity was carried out
by molecular imaging using a microPET/CT scanner. The effect of Mifepristone on the expression of angiogenic
factors after concomitant radio-chemotherapy was determined using a quantitative real-time PCR analysis of VEGF
gene expression.
Results: The analysis of the data shows a significant antitumoral effect by the simultaneous administration of
radiation-Mifepristone-Temozolamide in comparison with radiation alone or radiation-Temozolamide.
Conclusion: Our results suggest that Mifepristone could improve the efficacy of chemo-radiotherapy in
Glioblastoma. The addition of Mifepristone to standard radiation-Temozolamide therapy represents a potential
approach as a chemo-radio-sensitizer in treating GBMs, which have very limited treatment options.
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Glioblastoma multiforme (GBM) is the most common
tumor of the central nervous system, with a prognosis of
15 months median survival following diagnosis. GBM is
a fast-growing glioma that develops from astrocytes,
star-shaped glial cells that support nerve cells. GBM is
classified as a grade IV astrocytoma, which is the most
invasive type of glial tumor. This kind of tumor is highly
aggressive, growing rapidly and commonly spreading to
nearby brain tissue. Its treatment has been a challenge
due to its localization in the brain [1,2].
The standard treatment for GBM is surgery, followed by
radiation therapy [3,4] accompanied by chemotherapy. In
standard external radiation therapy (radiotherapy), multiple
sessions of standard-dose "radiation fractions" are delivered
to the tumor site as well as its margin in order to treat the* Correspondence: pgarcia_lopez@yahoo.com.mx
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distribution, and reproduction in any mediumzone of infiltrating tumor cells. Although the goal of radi-
ation therapy is to kill tumor cells selectively while leaving
normal brain tissue unharmed, in reality each treatment
session induces damage to both healthy and normal tissue,
which limits the benefit of radiotherapy.
The radiation dose that can be tolerated by the brain
is approximately 60 Gray. However, this dose is inad-
equate for total tumor eradication, resulting in a poor
treatment response in patients with glioma. Conse-
quently, the co-administration of chemotherapy with ra-
diation has been used in recent years with the intention
of improving treatment response [5,6].
Chemotherapy with the drug temozolamide is the
current standard treatment for GBM. The drug is ad-
ministered every day during radiation therapy and then
in six to eight cycles of five days (with a rest period be-
tween each cycle) at higher doses once radiation is com-
pleted [7]. While the aim of chemotherapy is long-term
tumor control, this goal is reached in only about 20 per-
cent of patients. That is overall patient survival withd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Antitumor activity on glioblastoma xenografts for
control and experimental groups. Ionizing radiation alone (Rad) or
combined with Temozolamide (Rad + Tmz), Mifepristone (Rad +Mife)
or both (Rad + Tmz +Mife). Each point represents the average ± SEM
of four to five animals. (*) indicates a significant difference (p < 0.05)
between the control and experimental groups; (†) and (‡) represent
a significant difference between Rad + Tmz +Mife vs. Rad and Rad +
Tmz +Mife vs. Rad + Tmz, respectively. (#) indicates a significant
difference between Rad vs. Rad +Mife.
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with the addition of chemotherapy to the treatment regi-
men [8,9]. Frequency of recurrence and rapid tumor
progression emphasize the need for treatment alterna-
tives to achieve long-term patient survival. Research ef-
forts currently underway are focused on two approaches:
(i) inhibition of angiogenesis in tumors, and (ii) the iden-
tification of agents that effectively and preferentially trig-
ger the cell death process in tumors.
The activation of angiogenesis, the formation of new
blood vessels from a preexisting vascular network, ap-
pears to play an important role in glioma development
and progression. Several studies have correlated in-
creased tumor vascularization with impaired patient sur-
vival [10,11]. Although there are a variety of factors that
promote angiogenesis, the main one is VEGF (vascular
endothelial growth factor) a regulator of endothelial cell
proliferation and capillary hyperpermeability involved in
malignant glioma.
Preclinical reports strongly suggest that antiangiogenic
therapy can have a clinical benefit due to a vascular
density reduction of tumors leading to a decrease in
tumor size [12,13]. However, the current antiangiogenic
therapies have shown only a moderate clinical efficacy,
with poor results in advanced glioblastoma.
Regarding the other current research focus in this
field, one possible agent for selectively triggering GBM
tumor cell death is Mifepristone, which is a compound
with activity as a progesterone and glucocorticoid recep-
tor antagonist. Consequently, the use of Mifepristone for
the inhibition of tumor cell growth has shown positive
results principally in hormone-dependent (e.g., breast,
prostate and ovarian) cancer.
Recently it was reported that vascular endothelial
growth factor (VEGF), epidermal growth factor receptor
(EGFR), cyclin D1 and progesterone receptor (PR) ex-
pression levels are elevated in patients with high–grade
astrocytomas and progesterone regulates astrocytomas
growth through its interaction with progesterone recep-
tor [14]. The same authors also demonstrated that pro-
gesterone increased VEGF and EGFR expression, and
cell proliferation in two human astrocytoma cell lines
derived from tumors of different evolution grades (U373
grade III and D54 grade IV) and these effects were
inhibited by Mifepristone [14,15]. Other authors have also
showed that the expression of VEGF in prostate cancer
cells DU 145 and PC3 treated with 10 micromol/L of
Mifepristone was significantly decreased [16].
As a chemosensitizing agent, Mifepristone has been
used to modulate the cytotoxic activity of doxorubicin
[17], paclitaxel [18] and cisplatin [19].
We previously reported that Mifepristone was able to
enhance the citotoxicity of cisplatin in cervical cancer
cells in vitro and in vivo by increasing the intracellular asintratumoral concentration of cisplatin [20]. In another
study using cervical cancer cells [21], we showed that the
combination of cisplatin with a pure antiestrogen, ICI
182,780, induced the arrest of the cell cycle at the G2/M
phase. The failure of this control checkpoint is believed to
lead to genomic instability, resulting in hypersensitivity to
radiation. However, the role of Mifepristone, alone or
combined with other drugs, has been poorly studied as a
chemo-radio-sensitizer.
The aim of the present study was to investigate
whether Mifepristone can modulate the growth of gli-
oma xenotrasplants treated with temozolamide and radi-
ation, and/or decrease of VEGF expression.
Results
After treatment of glioma xenografts with chemo-
radiotherapy, tumor growth was evaluated (Figure 1).
The tumor volume from control animals is showed up
to day 17. Due to the large size of tumors, animals were
sacrificed on that day. The statistical analysis shows no
differences in tumor growth during the first 10 days, but
starting from day 15 there was indeed a significant de-
crease in this value (p < 0.05) between the control and all
experimental groups. At day 17 the reduction in tumor
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ation alone: Rad) and 7-fold (Control vs. the combin-
ation of both chemotherapeutic agents and irradiation:
Rad + Tmz +Mife). At day 25, the statistical analysis indi-
cates that tumor volume of Rad + Tmz +Mife group was
significantly less from that of the Rad group (Power =
0.84) and Temozolamide group (Rad + Tmz) (Power =
0.84), but not from than of the Mifepristone group (Rad +
Mife). Statistical analysis also indicates a significantly
lesser tumor growth in the Rad +Mife group than the Rad
group (Power = 0.95). However, no difference was found
in tumor growth between Rad vs. Rad + Tmz, or between
Rad + Tmz vs. Rad +Mife.
Figure 2 shows tumor PET/CT image of a representa-
tive animal from each of the Rad, Rad + Tmz, Rad +Mife
and Rad + Tmz +Mife groups. Left images are baseline
at the beginning of treatments, and right images are at
day 25. Blue indicates 18F-FDG uptake, red arrows indi-
cate tumor location at baseline and day 25; green arrows
show sites of typical 18F-FDG uptake in brown adipose
tissue (BAT) in the neck of the mice. The physiologicalFigure 2 PET/CT images showing 18F-FDG tumor uptake. The groups a
represent the beginning of treatment (baseline) and right images the end
and day 25; green arrows show sites of typical 18F-FDG uptake in brown ad18F-FDG uptake in areas of supraclavicular fat has recently
been recognized as 18F-FDG uptake in brown adipose tis-
sue (BAT) using PET/CT technology. BAT functions as a
thermogenic organ by producing heat to maintain body
temperature in mammals, and it is generally in deep
cervical regions including the supraclavicular areas.
BAT is known to exhibit increases glucose uptake when
the sympathetic nervous system is activated by cold
stimulation [22]. Accordingly, the anesthesia used in
the animals subjected to PET/CT assays can decrease
the temperature slightly at the moment of imaging. In
our study, due to fact that the anesthesia used appeared
to decrease the temperature at the moment of imaging,
we observed a typical 18F-FDG uptake in BAT in the
neck of animals.
Images show the changes in metabolic activity after
treatments. Metabolic tumor volume, represented in
terms of the VOI [23], is depicted in Figure 3. There was
a significant difference between the VOI from the Rad
group and that of the groups with combined chemo-
radiotherapy treatments.re: Rad, Rad + Tmz, Rad +Mife and Rad + Tmz + Mife. Left images
of the study (day 25). Red arrows indicate tumor location at baseline
ipose tissue (BAT).
Figure 3 Metabolic activity of tumors, in terms of the VOI for
the different experimental groups. (*) indicates a significant
difference between the Rad group and the other experimental
groups (n = 2).
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change in weight was observed, indicating no systemic
toxicity with any of the treatments (radiotherapy alone or
combined with chemotherapy). Although there was light
weight loss at the beginning of the combination treatment
with irradiation plus Mifepristone and Temozolamide, the
weight of the animals in this group returned to the pre-
treatment values by the end of the study.Figure 4 Evaluation of body weight change. Mice treated with
radiation alone (○), radiation combined with Mifepristone (Δ) or
Temozolamide (▼), or radiation with the combination of both (■).
Controls (●) were treated only with vehicle. There was no significant
difference between groups. Data are presented as the means ± SEM
of four or five animals.Figure 5 shows the analysis of VEGF expression levels in
tumors at the end of the study. The results indicate that
compared to the control tumors, there was a significant
decrease in this value after all treatments (radiotherapy
alone or radiotherapy combined with Mifepristone and/or
Temozolamide). No difference was observed between any
of the groups with treatments, demonstrating that ioniz-
ing radiation alone or its combination with any of the
tested chemotherapy agents caused a marked reduction in
VEGF expression.
Discussion
To date, there is no effective therapy for GBM, a highly ag-
gressive tumor whose treatment has been a permanent
challenge. The current treatments of high-grade glioma pa-
tients with the combination of radiation and chemotherapy
can result in substantial lymphopenia, immunosuppression
and opportunistic infections compromising patient survival
[24]. Therefore, new alternatives are needed in order to in-
crease patient survival and avoid recurrence.
The present study aimed to evaluate whether the
introduction of Mifepristone, a progesterone and gluco-
corticoid receptor antagonist, to standard therapy with
Temozolamide and radiation improves the response of
glioma tumor in-vivo. The role of this antihormonal
agent as a chemo-radio-sensitizer in GBM treatment has
scarcely been explored.
We observed significant differences in tumor volume
growth between the control and treated groups (Figure 1).Figure 5 Quantitative Real-Time PCR analysis of VEGF relative
expression in C6 xenografts after each treatment. Analysis was
done on whole lysates from tumors removed on day 25.
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tant with radiation, tumor growth rate was slower than
with the radiation alone. Furthermore, the reduction of
tumor growth-rate was even more evident when we added
Mifepristone to the Temozolamide-Radiation scheme.
This suggests that Mifepristone can play an important role
in the chemo-radio-sensitization of GBM xenografts.
PET/CT images (Figure 2) illustrate the effect of the
different treatments, showing not only differences in
tumor size at day 25 but also variations in 18F-FDG up-
take in tumors, denoted by the blue-green color in the
tumor mass. The later is better visualized in terms of the
VOI values measured in the metabolic images from PET
(Figure 3); as mentioned before, the VOI measures the
volume concentration of 18F-FDG in the tumor and rep-
resents its metabolic activity. In this experiment we ob-
served that the size of the VOI (in cm3 or mm3) is not
always equal to the anatomical volume of the tumor
(compare ordinate-scale in Figures 2 and 3), as result of
the existent necrosis in some tumors (gray regions in tu-
mors from Rad and Rad-Tmz groups at day 25 in
Figure 2) where no uptake is observed. For this reasons
the VOI should be used as a more representative way to
evaluate the therapeutic response in tumors under treat-
ment. Our group is working in this topic by performing
some comparative studies between the simple measure-
ment of the dimension of the tumor and the VOI.
The Mifepristone dose used in our study was chosen
in accordance with previous reports in which a tumor
growth rate inhibition in ovarian and prostate xenografts
was observed [25,26]. However, the total accumulated
dose used in the present study was lower compared to
that used in any of the reports in the literature. Interest-
ingly, when patients with non-resectable meningioma
were chronically exposed to Mifepristone, no severe side
effects were observed [27]. Thus Mifepristone can be ad-
ministered for prolonged periods. In addition our results
demonstrated no significant change in the body weight
of animals, suggesting that Mifepristone could be ad-
ministered at higher doses.
Previous studies have shown that Mifepristone induces
G1-S blockage of the cell cycle through inhibition of cdk2
activity in human ovarian cancer cells [25]. A reduction in
cdK2 activity has been associated with an inhibition of
the transcription factor E2F1, which modulates S-phase
progression [28,29]. Accordingly, the induced chemo-
radiation-damage found in the present study might owe it-
self to the capacity of Mifepristone to arrest the G1-S
Phase of the cell cycle.
Another possible mechanism involved in the sensitizer
effect of this antihormonal agent is its antagonist action
on progesterone and glucocorticoid receptors. It is widely
accepted that progesterone participates in the develop-
ment of different types of cancer as a transcription factor[14,30,31]. It was reported [14,15] that progesterone-
receptor isoforms are expressed in two cell lines (U373
and D54) derived from high-grade human astrocytoma.
The same authors also demonstrated that progesterone in-
creased VEGF and EGFR expression and cell proliferation,
Mifepristone was able to inhibit not only the progesterone
effects but also when it was administered alone signifi-
cantly reduce astrocytoma cell growth in vitro.
It was reported that Mifepristone binds strongly to
glucocorticoid receptors, being its binding affinity for
these receptors approximately five and three times
greater than progesterone and dexamethasone, respect-
ively. Since the glioma C6 cells used in our study have
an elevated expression of glucocorticoid receptors, the
blockage of these receptors by Mifepristone probably led
to the receptor transactivation inhibition and therefore
the inhibition of cell proliferation.
Considering the extensive evidence that glioma cells
produce high levels of VEGF, and Mifepristone decreases
the expression of VEGF in prostate cancer cells [16],
breast cancer [32] and gastric cancer cells [33]; we also
investigated the possible participation of Mifepristone in
the inhibition of VEGF expression in glioma xenografts.
It was reported that the use of antiangiogenic therapies
in high-grade gliomas results in VEGF inhibition, im-
proving the vascular function and tumor oxygenation
that can increase the response to radiation [34].
To elucidate whether the treatment with radiation-
Mifepristone-Temozolamide acted on angiogenesis, we
evaluated the VEGF expression in GBM xenografts at
end of the experiments. However, radiation alone was
enough to drastically decrease VEGF production, so in
our experimental conditions was not possible to prove
the direct participation of Mifepristone on VEGF down-
regulation (Figure 5). Therefore, in future studies will be
necessary to performed different schemas of the treat-
ments that demonstrate the influence of Mifepristone on
VEGF expression.
More studies should be performed to understand the
mechanism by which Mifepristone acts, either by itself
or in combination with radiation and other drugs, to in-
hibit tumor growth. Tieszen CR et al. [35] reported that
growth inhibition of cancer cells by antiprogestin Mife-
pristone is not dependent upon expression of nuclear
progesterone receptors. They showed that Mifepristone
is able to inhibit the growth of in vitro cancer cells de-
rived from the nervous system, breast, prostate, ovary,
and bone, with an absence of expression of classic nu-
clear progesterone receptor in nearly all these cells.
Consequently, the potential action of Mifepristone in
chemo-radiation treatments of different tumors may be
mediated by other mechanisms, including its participa-
tion in apoptosis, cell cycle arrest, and expression of
ATM or other radiosensitizer proteins, mechanisms that
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may also be contributing to the reduction in size of glio-
blastoma xenografts found presently (Figure 1).
Conclusion
The present study suggests several possible mecha-
nisms for the significant decrease in GBM tumor size
found with the addition of Mifepristone to the treat-
ment with radiation or radiation plus temozolamide.
Whatever the possible mechanism, the current results
strongly suggest the potential of Mifepristone as a
chemo-radio-sensitizer for the standard treatments of
GBM tumors, for which currently available treatments
have shown limited effects.
Future studies are necessary to explain the mecha-
nisms related to the chemo-radio-sensitizing effect of
Mifepristone in GBM, not only on tumor xenografts but
also in ortotopic models of glioma.
Methods
Drugs and reagents
Mifepristone, Temozolamide and Trypsin were obtained
from Sigma Chemical Co. (St. Louis, MO, USA).
Dulbecco´s modified Eagle’s medium (DMEM), FCS (fetal
calf serum), EDTA (Ethylenediaminetetracetic acid), Tris
and SDS were obtained from Gibco, BRL (Grand Island,
NY, USA). High-quality water employed to prepare solu-
tions was obtained through a Milli-Q Reagent Water Sys-
tem (Continental Water Systems; El Paso, TX, USA).
Solutions
A stock solution (1 mg/mL) of Temozolamide was pre-
pared in DMSO, and Mifepristone was reconstituted in
Polietilenglicol-saline solution in a 50:50 mixture. All
standard solutions were stored at −20°C until use.
Animals
Female athymic Balb-C nu/nu mice, between 6–8 weeks
of age, were supplied by the Instituto Nacional de
Nutrición (INCMNSZ), Mexico City, Mexico. All animals
were kept in a pathogen-free environment and fed ad lib.
The procedures for care and use of the animals were
approved by the Ethics Committee of the Instituto
Nacional de Cancerología (INCan) (Mexico City, Mexico),
and all applicable institutional and governmental regula-
tions concerning the ethical use of animals were followed.
Cell cultures
The glioma C6 cell line used in this study (obtained from
ATCCW CCL-107™, Rockville, Maryland, USA) was cloned
from a rat glial tumor induced by N-nitrosomethylurea by
Benda et al. [36]. This cell line was routinely maintained
as a monolayer in DMEM supplemented with 5% fetal
bovine serum and incubated at 37°C in a 5% CO2atmosphere at high humidity. Cells were harvested with
0.025% Trypsin and 1 mM EDTA.
Tumor xenografts
Mice were subcutaneously (s.c.) inoculated with 1x106
C6-cells in the right flank. After inoculation, weekly
measurements of tumors were made. Two perpendicular
diameters were measured by using a caliper, and tumor
volume was determined by using the following relation:
V = π/6 × (large diameter × [short diameter]2). Once tu-
mors had reached approximately 50 mm3, the animals
were pair-matched into treatment and control groups
and the treatments were initiated. Each group consisted
of 4–5 tumor-bearing mice.
Irradiation procedure
Animals were anaesthetized with 1–3% isoflurane in
100% oxygen by using an animal anesthesia inhalation
unit (Bickford, Wales Center, NY), and irradiated with
an orthovoltage X-ray unit (D3225, Gulmay Medical
Ltd.,UK), as described previously [37]. Animals received
fractionated doses of 1 Gy per day for 10 days (Monday
to Friday for two weeks). The dose and the schedule
were selected in according to a dose–response curve
constructed in a previous pilot study. This curve showed
a 10 Gy dose as the ED50 (Dose of radiation to achieve
50% tumor growth inhibition). The X-ray beam was cen-
tered on the tumor lobe by using one of the different
lead collimators [37], depending on the tumor size at the
moment of irradiation.
Chemo-radiotherapy
Animals selected for this study were arranged in five
groups (n = 4–5 each), including: A) radiation treatment
alone (1 Gy/day for 10 days); B) irradiation (the same
scheme as in A) combined with Temozolamide (10 mg/
kg/day, i.p.); C) irradiation combined with Mifepristone
(12.5 mg/kg/day, s.c.); and D) irradiation combined with
Mifepristone and Temozolamide (the same scheme as in
B and C). Mifepristone and Temozolamide were admin-
istered in three cycles during three weeks, each cycle
consisting of three consecutive days (from Monday to
Wednesday). Control animals received only the vehicle
no irradiation. After each drug administration, mice
were weighed and the tumor volume was calculated, as
previously described (every five days). The experiment
was conducted during twenty-five days, at the end of
which time all animals were weighed and euthanized.
Tumor metabolic-evaluation by molecular imaging
Assessment of the metabolic tumor response was
performed in two animals of each group using a
microPET/CT scanner (Albira ARS, Oncovision Spain).
PET/CT images were acquired at the beginning of each
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under isoflurane anesthesia (1–3% isoflurane in 100%
oxygen), 30 min. after the intravenous injection of 200
μCi of 18F-FDG (fluorodeoxiglucose) by the caudal vein.
Metabolic tumor response, evaluated as 18F-FDG uptake
by active tumor cells, was measured by means of the
VOI (Volume of Interest). The latter is a tool that deter-
mines the volume concentration of the radiopharmaceu-
tical (volume radioactivity) in the entire tumor, and
represents the metabolic activity of the tumor [23]. VOIs
were measured over the tumor images by using the
image analysis software PMOD (PMOD Technologies
Ltd.) from regions with 18F-FDG uptake in tumors.
Average VOI-values in each group were compared to de-
pict tumor metabolic differences resulting from the dif-
ferent treatments.
VEGF expression analysis with Quantitative Real-Time PCR
The effect of Mifepristone on the expression of angiogenic
factors during concomitant chemo-radiotherapy was ex-
amined using quantitative real-time PCR (QrtPCR). VEGF
expression levels in the tumor tissue from glioma xeno-
grafts were evaluated at the end of the study. Briefly, the
whole tumors were lysed and the total RNA was isolated
from each tumor with a method based on guanidine iso-
thiocyanate/phenol/chloroform extraction using TRIzol
reagent (Invitrogen Life Technologies) and quantified with
UV spectroscopy. After quantification, 200 ng of total
RNA was used in the presence of the TaqManW RNA-to
-CT™ 1-Step Kit (Applied Biosystems) to perform one-
step RT-PCR TaqMan Gene Expression Assays of vascular
endothelial growth factor A (VEGF-A) (Hs00900055_m1,
Applied Biosystems) by using a FAM probe and Endogen-
ous Control Human GAPDH (4310884E, Applied
Biosystems) with VIC Probe. Real-time quantization was
realized on the Spectrum 48 thermocycler Instrument
(Esco, Micro Pte Ltd, Singapore).
PCR reactions were carried out in a total volume of 10 μL.
The reaction conditions were as follows: pre-incubation
at 60°C for 15 min and 94°C for 5 min, followed by 40
cycles (amplification) at 94°C for 15 s and 60°C for 60 s.
Fluorescence emission spectra were monitored and an-
alyzed. PCR products were measured by the threshold
cycles (TC), at which specific fluorescence became de-
tectable. The TC was used for kinetic analysis and was
proportional to the initial number of target copies in
the sample. Analysis of relative gene expression was
based on the 2-ΔΔCTmethod. The analysis was carried
out with four to five independent samples.
Statistical analysis
Values are reported as the mean ± SEM. Statistical ana-
lysis was performed using one-way analysis of variance
(ANOVA) to compare tumor volumes or VOIs betweengroups, using SPSS Base 20.0 software (SPSS Inc.,
Chicago, IL). Differences were statistically compared
using multiple comparisons between-groups. When ne-
cessary, comparison of means was Bonferroni adjusted.
A log transformation was applied to the data to better
satisfy the assumptions underlying the analysis. The
means and standard errors were computed from un-
transformed data and analysis of statistical significance
(p < 0.05) was based on transformed data. A statistical
power of analysis was done and a (1-β) > 0.80 was con-
sidered sufficient to reject the possibility of a Type I
error [38].
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